Valneva responds to french government's call for vaccine supply of ixchiq® against chikungunya outbreak in la rÉunion

Saint herblain (france), march 24, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in france's island of la rÉunion with its vaccine ixchiq®. in agreement and with support from the local public health agency, the agence rÉgionale de santÉ la rÉunion, valneva will provide 40,000 doses starting early april, with an option to provide more, through distribution agreements with the island's wholesalers. this supply of doses, paid for by the french authorities, is in line with the recommendation of france's national public health agency, the haute autoritÉ de santÉ (has), to prioritize for vaccination adults aged 65 and over, with co-morbidities. ixchiq® remains available for purchase in france (mainland and overseas).
VALN Ratings Summary
VALN Quant Ranking